JP2022508609A5 - - Google Patents
Info
- Publication number
- JP2022508609A5 JP2022508609A5 JP2021543970A JP2021543970A JP2022508609A5 JP 2022508609 A5 JP2022508609 A5 JP 2022508609A5 JP 2021543970 A JP2021543970 A JP 2021543970A JP 2021543970 A JP2021543970 A JP 2021543970A JP 2022508609 A5 JP2022508609 A5 JP 2022508609A5
- Authority
- JP
- Japan
- Prior art keywords
- hypertonic solution
- composition
- solution according
- interstitium
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024064529A JP2024099600A (ja) | 2018-10-04 | 2024-04-12 | 血漿浸透圧を操作することによるグリンパティック送達の改善 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862741295P | 2018-10-04 | 2018-10-04 | |
| US62/741,295 | 2018-10-04 | ||
| PCT/US2019/053808 WO2020072357A1 (en) | 2018-10-04 | 2019-09-30 | Improvement of glymphatic delivery by manipulating plasma osmolarity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024064529A Division JP2024099600A (ja) | 2018-10-04 | 2024-04-12 | 血漿浸透圧を操作することによるグリンパティック送達の改善 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022508609A JP2022508609A (ja) | 2022-01-19 |
| JP2022508609A5 true JP2022508609A5 (https=) | 2022-06-08 |
| JP7611149B2 JP7611149B2 (ja) | 2025-01-09 |
Family
ID=68502006
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543970A Active JP7611149B2 (ja) | 2018-10-04 | 2019-09-30 | 血漿浸透圧を操作することによるグリンパティック送達の改善 |
| JP2024064529A Withdrawn JP2024099600A (ja) | 2018-10-04 | 2024-04-12 | 血漿浸透圧を操作することによるグリンパティック送達の改善 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024064529A Withdrawn JP2024099600A (ja) | 2018-10-04 | 2024-04-12 | 血漿浸透圧を操作することによるグリンパティック送達の改善 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12311035B2 (https=) |
| EP (1) | EP3860564A1 (https=) |
| JP (2) | JP7611149B2 (https=) |
| KR (1) | KR20210100086A (https=) |
| CN (1) | CN113226283A (https=) |
| AU (1) | AU2019354965B2 (https=) |
| CA (1) | CA3115071A1 (https=) |
| WO (1) | WO2020072357A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023538831A (ja) * | 2020-08-03 | 2023-09-12 | トランスルミナル、システムズ、リミテッド、ライアビリティー、カンパニー | 病理組織の経動脈浸透圧塞栓形成のためのデバイスおよび方法 |
| WO2023073526A1 (en) * | 2021-10-25 | 2023-05-04 | Novartis Ag | Methods for improving adeno-associated virus (aav) delivery |
| JP2026510233A (ja) | 2023-02-16 | 2026-04-02 | ユニバーシティー オブ ロチェスター | グリンパ－リンパ流出の改善 |
| US12483569B2 (en) | 2024-03-28 | 2025-11-25 | Bank Of America Corporation | System and method for identifying unauthorized data traffic in a computing network |
| WO2025250454A1 (en) * | 2024-05-28 | 2025-12-04 | University Of Rochester | Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869248A (en) | 1994-03-07 | 1999-02-09 | Yale University | Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences |
| US5599706A (en) | 1994-09-23 | 1997-02-04 | Stinchcomb; Dan T. | Ribozymes targeted to apo(a) mRNA |
| US6083702A (en) | 1995-12-15 | 2000-07-04 | Intronn Holdings Llc | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| ATE354957T1 (de) | 1995-12-15 | 2006-03-15 | Intronn Inc | Durch trans-spaltung erhaltene therapeutische molekule |
| DE1257584T1 (de) | 2000-02-24 | 2003-05-28 | Lilly Co Eli | Humanisierte antikörper, die amyloid beta peptid demarkieren |
| CA2441903C (en) | 2000-05-26 | 2012-07-31 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| CA2414772C (en) | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| WO2003016467A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass |
| CA2451998A1 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Anti-a.beta. antibodies |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| WO2004029629A1 (en) | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
| US20040146512A1 (en) | 2002-10-09 | 2004-07-29 | Arnon Rosenthal | Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
| US20050142141A1 (en) | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
| EA200501524A1 (ru) | 2003-03-28 | 2006-06-30 | Сентокор, Инк. | Антитела против амилоида, композиции, способы и применения |
| TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
| US8801541B2 (en) | 2007-09-27 | 2014-08-12 | Taylor Made Golf Company, Inc. | Golf club |
| WO2006014638A2 (en) * | 2004-07-19 | 2006-02-09 | The General Hospital Corporation | ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| WO2006039470A2 (en) | 2004-09-29 | 2006-04-13 | Centocor, Inc. | Anti- amyloid antibodies, compositions, methods and uses |
| CA2589017A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Amyloid beta antibodies for use in improving cognition |
| EP1838348B1 (en) | 2004-12-15 | 2013-06-26 | Janssen Alzheimer Immunotherapy | Humanized amyloid beta antibodies for use in improving cognition |
| US7625560B2 (en) | 2004-12-15 | 2009-12-01 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| ES2259270B1 (es) | 2005-03-09 | 2007-11-01 | Consejo Superior De Investigaciones Cientificas | Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal. |
| WO2009027105A2 (en) | 2007-08-31 | 2009-03-05 | Neurimmune Therapeutics Ag | Method of providing patient specific immune response in amyloidoses and protein aggregation disorders |
| EP3000481A3 (en) | 2009-07-14 | 2016-05-11 | Mayo Foundation for Medical Education and Research | Peptide-mediated non-covalent delivery of active agent agents across the blood brain barrier |
| US9676849B2 (en) | 2012-01-10 | 2017-06-13 | Biogen Ma Inc. | Enhancement of transport of therapeutic molecules across the blood brain barrier |
| EP2964270A4 (en) | 2013-02-21 | 2017-03-22 | University Of Rochester | Methods for evaluating brain-wide paravascular pathway for waste clearance function and methods for treating neurodegenerative disorders based thereon |
| US10508151B2 (en) | 2014-11-19 | 2019-12-17 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
| US10907176B2 (en) | 2015-01-14 | 2021-02-02 | The University Of North Carolina At Chapel Hill | Methods and compositions for targeted gene transfer |
| US10632080B2 (en) | 2015-09-11 | 2020-04-28 | The Johns Hopkins University | Compositions and methods to improve nanoparticle distribution within the brain interstitium |
| US10123969B2 (en) * | 2015-10-15 | 2018-11-13 | Wisconsin Alumni Research Foundation | Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid |
| WO2017123757A1 (en) * | 2016-01-15 | 2017-07-20 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of neurologic disease |
| WO2017210343A1 (en) * | 2016-06-01 | 2017-12-07 | The University Of Virginia Patent Foundation | Methods and compositions for modulating lymphatic vessels in the central nervous system |
| ES2954171T3 (es) * | 2016-07-20 | 2023-11-20 | P&X Medical Nv | Compuestos para su uso en métodos para tratar glaucoma y enfermedades de la retina |
| US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
-
2019
- 2019-09-30 CN CN201980075683.8A patent/CN113226283A/zh active Pending
- 2019-09-30 EP EP19801124.9A patent/EP3860564A1/en active Pending
- 2019-09-30 WO PCT/US2019/053808 patent/WO2020072357A1/en not_active Ceased
- 2019-09-30 US US17/280,606 patent/US12311035B2/en active Active
- 2019-09-30 JP JP2021543970A patent/JP7611149B2/ja active Active
- 2019-09-30 CA CA3115071A patent/CA3115071A1/en active Pending
- 2019-09-30 AU AU2019354965A patent/AU2019354965B2/en active Active
- 2019-09-30 KR KR1020217013589A patent/KR20210100086A/ko active Pending
-
2024
- 2024-04-12 JP JP2024064529A patent/JP2024099600A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022508609A5 (https=) | ||
| Hernandez et al. | Liposome based drug delivery as a potential treatment option for Alzheimer's disease | |
| US12496345B2 (en) | Method of treating cancer | |
| Talegaonkar et al. | Intranasal delivery: An approach to bypass the blood brain barrier | |
| JP2016074740A5 (https=) | ||
| US20210069354A1 (en) | Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier | |
| JP2008520544A5 (ja) | 癌関連疲労の治療または予防のための医薬の製造への使用方法 | |
| RU2002115406A (ru) | Соединение, обладающее свойствами высвобождения гормона роста | |
| CA2387095A1 (en) | Compound with growth hormone releasing properties | |
| US20220062412A1 (en) | Treatment of alzheimer's disease (ad) with an aluminum salt | |
| Ye et al. | Macrophages as nanocarriers for drug delivery: novel therapeutics for central nervous system diseases | |
| Wu et al. | Brain delivery strategies for biomacromolecular drugs: intranasal administration | |
| Malhotra et al. | Devices to overcome the buccal mucosal barrier to administer therapeutic peptides | |
| EP4548924A3 (en) | Enhanced delivery of drugs and other compounds to the brain and other tissues | |
| US11065273B2 (en) | Treatment and prevention of alzheimer's disease (AD) | |
| JP2009542609A5 (https=) | ||
| JP2020503318A5 (https=) | ||
| JP2024518426A5 (https=) | ||
| Rajkonwar et al. | Blood–Brain Barrier as a Point of Concern for Neural Drug Delivery: Problems and Advancements | |
| Sharma et al. | Unravelling Nanotherapeutics for Treatment of Neuroinfectious Diseases | |
| Parra et al. | Perspectives of Nanoscience and Nanotechnology in Medicine and Pharmacy | |
| Mamada et al. | Brain Diseases: An Introduction and the Need for Novel Drug-Delivery Approaches | |
| Stepensky | Delivery of peptides and proteins to the brain using nano-drug delivery systems and other formulations | |
| Gurnell et al. | Sustained Improvement in Clinical Efficacy, Asthma Control, and Quality of Life in Patients With Severe, Oral Corticosteroid (OCS)-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study | |
| JP2023532736A5 (https=) |